Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 47 articles:
HTML format
Text format



Single Articles


    April 2017
  1. JANSSEN A, Verkleij CP, van der Vlist A, Mathijssen RH, et al
    Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  2. MITTAL K, Donthamsetty S, Kaur R, Yang C, et al
    Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  3. LIN HM, Mahon KL, Spielman C, Gurney H, et al
    Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
    Br J Cancer. 2017 Mar 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    February 2017
  4. LEHTO US, Tenhola H, Taari K, Aromaa A, et al
    Patients' perceptions of the negative effects following different prostate cancer treatments and the impact on psychological well-being: a nationwide survey.
    Br J Cancer. 2017 Feb 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  5. ROCHETTE A, Boufaied N, Scarlata E, Hamel L, et al
    Asporin is a stromally expressed marker associated with prostate cancer progression.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    December 2016
  6. RAO SR, Snaith AE, Marino D, Cheng X, et al
    Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer.
    Br J Cancer. 2016 Dec 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  7. WALTER SD, de Koning HJ, Hugosson J, Talala K, et al
    Impact of cause of death adjudication on the results of the European prostate cancer screening trial.
    Br J Cancer. 2016 Nov 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  8. THURTLE D, Hsu RC, Chetan M, Lophatananon A, et al
    Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer.
    Br J Cancer. 2016 Nov 1. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  9. DELL'OGLIO P, Stabile A, Gandaglia G, Briganti A, et al
    Comment on 'Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome'.
    Br J Cancer. 2016 Oct 25. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  10. BERNEY DM
    Reply to 'Comment on "Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome"'.
    Br J Cancer. 2016 Oct 25. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  11. KAAPU KJ, Murtola TJ, Talala K, Taari K, et al
    Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  12. LARKIN SE, Johnston HE, Jackson TR, Jamieson DG, et al
    Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  13. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  14. JONSSON M, Ragnum HB, Julin CH, Yeramian A, et al
    Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
    Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  15. DE MORREE ES, Bottcher R, van Soest RJ, Aghai A, et al
    Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  16. KHANKARI NK, Murff HJ, Zeng C, Wen W, et al
    Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  17. STUOPELYTE K, Daniunaite K, Bakavicius A, Lazutka JR, et al
    The utility of urine-circulating miRNAs for detection of prostate cancer.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    July 2016
  18. YAMAMOTO Y, Offord CP, Kimura G, Kuribayashi S, et al
    Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy.
    Br J Cancer. 2016;115:195-202.
    PubMed     Text format     Abstract available


    June 2016
  19. GREEN WJ, Ball G, Hulman G, Johnson C, et al
    KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  20. WANG W, Yang M, Kenfield SA, Hu FB, et al
    Nut consumption and prostate cancer risk and mortality.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  21. TURNER EL, Metcalfe C, Donovan JL, Noble S, et al
    Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  22. SHAROVA E, Grassi A, Marcer A, Ruggero K, et al
    A circulating miRNA assay as a first-line test for prostate cancer screening.
    Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  23. EPSTEIN JI
    New prostate cancer grade group system correlates with prostate cancer death in addition to biochemical recurrence.
    Br J Cancer. 2016;114:1069-70.
    PubMed     Text format    


    April 2016
  24. CHAUDHARY AK, Bhat TA, Kumar S, Kumar A, et al
    Mitochondrial dysfunction-mediated apoptosis resistance associates with defective heat shock protein response in African-American men with prostate cancer.
    Br J Cancer. 2016 Apr 26. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  25. BERNEY DM, Beltran L, Fisher G, North BV, et al
    Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome.
    Br J Cancer. 2016 Apr 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  26. AHMED M, Dorling L, Kerns S, Fachal L, et al
    Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
    Br J Cancer. 2016 Apr 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  27. GOTO Y, Kojima S, Kurozumi A, Kato M, et al
    Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer.
    Br J Cancer. 2016 Apr 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  28. GRAFF RE, Meisner A, Ahearn TU, Fiorentino M, et al
    Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.
    Br J Cancer. 2016 Mar 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  29. BYRNE NM, Nesbitt H, Ming L, McKeown SR, et al
    Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.
    Br J Cancer. 2016;114:659-68.
    PubMed     Text format     Abstract available


  30. SAUNDERS EJ, Dadaev T, Leongamornlert DA, Olama AA, et al
    Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
    Br J Cancer. 2016 Mar 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  31. ZHOU CK, Sutcliffe S, Welsh J, Mackinnon K, et al
    Is birthweight associated with total and aggressive/lethal prostate cancer risks? A systematic review and meta-analysis.
    Br J Cancer. 2016 Mar 1. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    February 2016
  32. MARSHALL DC, Webb TE, Hall RA, Salciccioli JD, et al
    Trends in UK regional cancer mortality 1991-2007.
    Br J Cancer. 2016;114:340-7.
    PubMed     Text format     Abstract available


    January 2016
  33. GILBERT SE, Tew GA, Fairhurst C, Bourke L, et al
    Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer.
    Br J Cancer. 2016 Jan 14. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    December 2015
  34. GISKEODEGARD GF, Hansen AF, Bertilsson H, Gonzalez SV, et al
    Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
    Br J Cancer. 2015 Dec 3. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    November 2015
  35. BOTTCHER R, Henderson DJ, Dulla K, van Strijp D, et al
    Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
    Br J Cancer. 2015;113:1502-1511.
    PubMed     Text format     Abstract available


    September 2015
  36. PASHAYAN N, Pharoah PD, Schleutker J, Talala K, et al
    Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.
    Br J Cancer. 2015;113:1086-93.
    PubMed     Text format     Abstract available


  37. PUNNOOSE EA, Ferraldeschi R, Szafer-Glusman E, Tucker EK, et al
    PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.
    Br J Cancer. 2015 Sep 17. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  38. GOTO Y, Kojima S, Nishikawa R, Kurozumi A, et al
    MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
    Br J Cancer. 2015 Sep 1. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  39. HASHIBE M, Galeone C, Buys SS, Gren L, et al
    Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort.
    Br J Cancer. 2015;113:809-16.
    PubMed     Text format     Abstract available


    August 2015
  40. OLSSON CE, Alsadius D, Pettersson N, Tucker SL, et al
    Patient-reported sexual toxicity after radiation therapy in long-term prostate cancer survivors.
    Br J Cancer. 2015 Aug 4. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    July 2015
  41. REIS IM, Ramachandran K, Speer C, Gordian E, et al
    Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease.
    Br J Cancer. 2015;113:460-8.
    PubMed     Text format     Abstract available


    June 2015
  42. MITCHELL T, Neal DE
    The genomic evolution of human prostate cancer.
    Br J Cancer. 2015 Jun 30. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  43. XU S, Adisetiyo H, Tamura S, Grande F, et al
    Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.
    Br J Cancer. 2015 Jun 23. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  44. CUZICK J, Stone S, Fisher G, Yang ZH, et al
    Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
    Br J Cancer. 2015 Jun 23. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  45. SULLIVAN J, Kopp R, Stratton K, Manschreck C, et al
    An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality.
    Br J Cancer. 2015 Jun 11. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    April 2015
  46. HIRST AM, Simms MS, Mann VM, Maitland NJ, et al
    Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells.
    Br J Cancer. 2015;112:1536-45.
    PubMed     Text format     Abstract available


    March 2015
  47. MCPHAIL S, Johnson S, Greenberg D, Peake M, et al
    Stage at diagnosis and early mortality from cancer in England.
    Br J Cancer. 2015;112 Suppl 1:S108-15.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: